| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 76,43 | 76,66 | 10:18 | |
| 76,54 | 76,70 | 13.03. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 96,90 | 65 | |||
| 96,00 | 75 | |||
| 92,00 | 230 | |||
| 88,22 | 100 | |||
| 85,80 | 17 | |||
| 84,90 | 20 | |||
| 78,90 | 50 | |||
| 77,45 | 50 | |||
| 76,59 | 105 | |||
| 76,58 | 252 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/snw.htm [/URL] | ||||
| 252 | 76,49 | |||
| 105 | 76,42 | |||
| 80 | 76,00 | |||
| 40 | 75,00 | |||
| 130 | 74,86 | |||
| 150 | 74,00 | |||
| 110 | 73,00 | |||
| 25 | 69,90 | |||
| 20 | 64,23 | |||
| 1.036 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.948 | 0,495 | 964 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 13.03.2026 | 17:35:45 | 76,41 | 142 |
| 13.03.2026 | 17:28:39 | 76,40 | 40 |
| 13.03.2026 | 17:28:39 | 76,40 | 10 |
| 13.03.2026 | 17:28:39 | 76,40 | 9 |
| 13.03.2026 | 17:21:01 | 76,40 | 480 |
| 13.03.2026 | 17:21:01 | 76,39 | 392 |
| 13.03.2026 | 17:21:01 | 76,38 | 510 |
| 13.03.2026 | 17:21:01 | 76,37 | 167 |
| 13.03.2026 | 17:21:01 | 76,36 | 260 |
| 13.03.2026 | 17:21:01 | 76,35 | 117 |
| 13.03.2026 | 17:21:01 | 76,34 | 74 |
| 13.03.2026 | 17:20:30 | 76,33 | 11 |
| 13.03.2026 | 17:20:29 | 76,34 | 9 |
| 13.03.2026 | 17:17:51 | 76,29 | 17 |
| 13.03.2026 | 17:17:29 | 76,29 | 142 |
| 13.03.2026 | 17:14:50 | 76,32 | 35 |
| 13.03.2026 | 17:12:17 | 76,35 | 23 |
| 13.03.2026 | 17:11:34 | 76,33 | 20 |
| 13.03.2026 | 17:07:33 | 76,34 | 34 |
| 13.03.2026 | 17:06:26 | 76,27 | 77 |
| Tagesumsatz Xetra | -0,12 -0,16 % | 18.208 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Vaxart signals $700M COVID-19 vaccine milestone path as Sanofi partnership advances and 2026 data readouts approach | 18 | Seeking Alpha | ||
| Do | Sanofi: Information concerning the total number of voting rights and shares - February 2026 | 11 | GlobeNewswire (USA) | ||
| SANOFI Aktie jetzt für 0€ handeln | |||||
| Do | Sanofi mit Chance auf Bodenbildung: antizyklische Doppelstrategie könnte interessant sein | Société Générale | |||
| Di | Sanofi - 6-K, Report of foreign issuer | 13 | SEC Filings | ||
| 06.03. | Sanofi strikes deal with Brazil's EMS to sell generics manufacturer Medley | 50 | FiercePharma |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Fr | EQT exits Galderma Group AG in full via largest sponsor-backed block trade ever | PR Newswire | EQT completes final sell-down in Galderma, a global dermatology company delivering science-backed solutions to healthcare professionals, consumers and patients worldwideUnder EQT's ownership... ► Artikel lesen | |
| Do | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | GlobeNewswire (Europe) | TONMYA (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA... ► Artikel lesen | |
| Fr | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | AFX News | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| Fr | Im Windschatten von Novo Nordisk: Dänisches Pharma-IPO voraus? | Der Aktionär | Dänemark und Pharma? In diesem Zusammenhang führt kein Weg an Novo Nordisk vorbei. Das Unternehmen, dessen Wurzeln bis ins Jahr 1923 reichen, war einst das wertvollste börsennotierte Unternehmen Europas.... ► Artikel lesen | |
| Do | TerrAscend Reports Fourth Quarter and Full Year 2025 Financial Results | GlobeNewswire (Europe) | Net Revenue of $66.1 million for Q4 2025 and $260.6 Million for FY 2025 Gross Profit Margin of 52.1% for Q4 2025 and 52.3% for FY 2025 from continuing operations Q4 2025 Net Cash provided from continuing... ► Artikel lesen |